RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: In humans and in vivo model systems, loss of RUNX1 leads to increased susceptibility to AML; point mutations are associated with shorter time to progression from MDS to AML and worse prognosis in AML and CML.97,98 In contrast, for RUNX1 translocations, a survival dependency on WT RUNX1 has been reported.99